Table 2.

Summary of studies on MSN complexes with platinum drugs.

Platinum Drug	Organosilicon Nanocarrier	Other Ligand/Carrier/Drug	Targeting Ligand	Cell line/IC50	Size (nm)	Refs.
cisplatin	amine-functionalized mesoporous silica (AMS)	nitric oxide		H596/45.3 μM A549/69.1 μM WI-38/58.6 μM BEAS2B/9.1 μM	~50 nm (AMS)	[64]
cisplatin	MSN-PEG MSN-PEI MSN-SH			-	~140 nm (nanocarriers)	[68]
cisplatin	MSN (containing thiol groups)	6-mercaptopurine		-	98 nm–115 nm	[71]
cisplatin	MSN	PEG-PDS	peptide Arg-Gly-Asp-D -Phe-Cys (cRGDfC)	KB cells	~200 nm (nanocarrier)	[72]
cisplatin	MSN-NH2	Polyelectrolyte: cationic poly (allylamine hydrochloride) and negatively charged P(DMA-co-TPAMA), model drug-rhodamine		-	~150 nm (MSN-NH2)	[73]
cisplatin	MSNP SiNP			C6	~100 nm	[74]
carboplatin, oxaliplatin, cisplatin	MSN	DOPC lipid 165Ho		-	82 nm (165Ho-MS)	[63]
activated Pt drugs	MSN	PEG		-	-	[77]
cisplatin	MSN	poly[(N-isopropylacrylamide)-co-(methacrylic acid)]	folic acid	Hep2	-	[82]
cisplatin	MSN		folic acid	LN18/149 μg/mL	100 nm (MNS)	[84]
cisplatin	MSN		vitamin B12	-	316 ± 6	[85]
cisplatin	MSN	polyethyleneimine HNF4α		CD133− and CD133+ Huh7 cells	243.1 nm	[91]
cisplatin	MSN	doxorubicin, bovine serum albumin	cyclodextrin and folic acid	HeLa	173 ± 9 nm	[92]
cisplatin	layer of microporous silica and tetrasulfide-bridged organic silica	acriflavine mPEG-silane		A549	-	[96]
cisplatin	MSN functionalized with APTES and glutaraldehyde	collagen		A549	189.6 ± 5.2 nm	[97]
cisplatin	MSN	aluminum chloride phthalocyanine		HeLa/4.2 µM	96.5 ± 10.5 (MNS) 112.7 ± 19.5 (AlClPc/cisplatin-MSNs)	[99]
cisplatin	monodisperse spherical hydrophilic silica (HYPS)	CuFe2O4		MCF-7	80 nm (HYPS)	[101]
cisplatin	mesoporous silica	magnetic particles (Fe3O4), PEG		HeLa MCF-7	50 nm	[103]
cisplatin	polyamide membranes			GM07492A/23.95 μgM		[104]